

Prasugrel Compared with Clopidogrel in Patients with ST-Elevation MI Undergoing Percutaneous Coronary Intervention

- Analysis of the TRITON TIMI-38 STEMI cohort -


Comment

Franz-Josef Neumann
Herz-Zentrum Bad Krozingen



Key Message: Superior net clinical benefit in STEMI

15-month incidence of death/MI/stroke or major non-CABG bleeding (%)




Comparison of STEMI and UA/NSTEMI cohorts

	STEMI (n = 3,534)	UA/NSTEMI (n = 10,074)	P
Age > 75 years (%)	11.5	13.9	< 0.001
Diabetes (%)	19.1	24.5	< 0.001
Hypertension (%)	49.7	69.0	< 0.001
Use of GP IIb/IIIa inhibitors (%)	63.0	51.5	< 0.001




Similar Efficacy in STEMI and UA/NSTEMI

15-month incidence of death/MI/stroke (%)




Superior Safety in STEMI versus UA/NSTEMI

30-day incidence of TIMI major non-CABG bleed (%)



Superior Safety in STEMI versus UA/NSTEMI

30-day incidence of TIMI major non-CABG bleed (%)



Role of peri-interventional GP IIb/IIIa inhibition?



Analysis of the TRITON TIMI-38 STEMI cohort: Caveats – Open Questions

Prespecified secondary analysis of subset

Adjustments for inhomogeneities between study arms in subset (such as age, Killip class)

Interaction with GP IIb/IIIa inhibition

Interaction with timing of study drug (before, during, after PCI)


Role of primary versus secondary PCI

Reduction of periinterventional risk vs. secondary prevention



TRITON STEMI in Perspective: ISAR-2 & BRAVE-3

30-day incidence of death/reMI/urgent TVR (%)




Important role of early effective P_2Y_{12} -receptor blockade




Superior antiplatelet effect of prasugrel vs. clopidogrel

Inhibition of platelet aggregation (20 μ M ADP, %)



TRITON STEMI cohort in perspective

30-day all cause mortality (%)




Prasugrel Compared with Clopidogrel in Patients with ST-Elevation MI Undergoing Percutaneous Coronary Intervention

- Analysis of the TRITON TIMI-38 STEMI cohort -

Back-up slides




Stent Thrombosis in STEMI and UA/NSTEMI




Stent Thrombosis in STEMI and UA/NSTEMI

15-month incidence of stent thrombosis (%)




All Cause Mortality in STEMI and UA/NSTEMI

15-month all cause mortality (%)



TIMI major non-CABG bleeding

Proportion of patients (%)



Role of peri-interventional GP IIb/IIIa inhibition?

